Thera-SAbDab

RAVULIZUMAB

>   Structural Summary
TherapeuticRavulizumab
TargetC5
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv Structure5i5k [Fvs: HL, XY]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Ravulizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.13%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
ravulizumab Q V Q L V Q S G A E V K K P G A S V K V S C K A S G H I F S N Y W I Q W V R Q A P G Q G L E W M G E I L P G S G H T E Y T E N F K D R V T M T R D T S T S T V Y M E L S S L R S E D T A V Y Y C A R Y F F G S S P N W Y F D V W G Q G T L V T V S S
5i5k Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y I F S N Y W I Q W V R Q A P G Q G L E W M G E I L P G S G S T E Y T E N F K D R V T M T R D T S T S T V Y M E L S S L R S E D T A V Y Y C A R Y F F G S S P N W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ravulizumab D I Q M T Q S P S S L S A S V G D R V T I T C G A S E N I Y G A L N W Y Q Q K P G K A P K L L I Y G A T N L A D G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q N V L N T P L T F G Q G T K V E I K
5i5k D I Q M T Q S P S S L S A S V G D R V T I T C G A S E N I Y G A L N W Y Q Q K P G K A P K L L I Y G A T N L A D G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q N V L N T P L T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedAlexion Pharmaceuticals
Conditions ApprovedParoxysmal nocturnal haemoglobinuria
Conditions ActiveHaemolytic uraemic syndrome, Myasthenia gravis, IgA nephropathy
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]